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DOI: http://dx.doi.org/10.1016/j.hemonc.2013.09.002BACKGROUND AND OBJECTIVES: The role of bone marrow-mesenchymal stem cells (BM-MSC) in leukae-
mic cell control is controversial. The purpose of this work was to evaluate BM-MSC role regarding the viability,
proliferation and immunophenotype of normal B-cell precursors from control (Ct) patients and leukaemic cells
from B-acute lymphoblastic leukaemia (B-ALL) patients.
PATIENTS AND METHODS: BM-MSC were isolated and characterised from voluntary donors. Mononuclear
cells isolated from Ct and B-ALL bone marrow samples were cultured in the presence or absence of
BM-MSC for 7 days. Cell viability was determined with LIVE/DEAD and proliferation index evaluated by CFSE
labelling. Cell population immunophenotypes were characterised by estimating CD19, CD10, CD20 and CD45
antigens by flow cytometry.
RESULTS: After co-culture, B-ALL cells exhibited higher viability (20–40%) as compared to just cells (3–10%).
Ct and B-ALL absolute cell counts were higher in the presence of BM-MSC (Ct: 25/mm3 cf 8/mm3, B-ALL: 15/
mm3 cf 3/mm3). Normal B-cell subpopulations in co-culture had increased expression of CD19 and CD10 (Pre-
pre B) and CD45 and CD20 antigens (Pre-B). B-ALL cells co-cultured with BM-MSC showed an increase in
CD19 and CD20, although the greatest increase was observed in the CD10 antigen.
CONCLUSIONS: Lymphoid cell maintenance, at early stages of differentiation, was significantly promoted by
BM-MSC in normal and leukaemic cells. Co-cultures also modulated the expression of antigens associated with
the B-ALL asynchronous phenotype as CD10 co-expressed with CD19 and CD20. To our knowledge, this is the
first time that CD10, CD19 and CD20 leukaemic antigens have been reported as being regulated by BM-MSC.Haematopoiesis is a physiological processwhich depends on hematopoietic stem cell(HSC) ability to self-renew, proliferate or
differentiate.1,2 Since Schoﬁeld’s niche was proposed
30 years ago, researchers have learned that more than
10 cell populations may interact with HSC through
adhesion molecules and/or different soluble factors.3
Bone marrow mesenchymal stem cells (BM-MSC)
are particularly important hematopoietic regulatorsHematol Oncol Stem Cell Ther 6(3–4) Fourth Quarter 2013 hemoncstem.edmgr.due to their capacity to differentiate into specialised
stromal cells and produce soluble factors promoting
primitive hematopoietic cell maintenance.4–6 This
capacity has been extensively used for in vitro HSC
expansion, preserving stemness properties, that is,
self-renewal and differentiation potential.7,8 This has
been useful in preserving myeloid populations but it
has been not fully investigated in lymphoid progeni-
tors.9 Also, few studies dealt with human lymphocytecom 89
90
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immunophenotypic changes in vitro co-cultured with
BM-MSC.10 In spite of this, the differentiation pat-
tern of committed progenitors such as the B-cell line-
age has been accurately dilucidated.10–12
B-cell lineage hierarchical organisation begins with
Pre-pre B-cells, where CD19 is ﬁrst expressed to-
gether with CD10, CD34, CD79a and nuclear termi-
nal deoxynucleotidyl transferase (TdT) markers.
These cells then differentiate into Pre-B cells express-
ing cytoplasmic Igl (cy-Igl); they up-regulate CD45
without CD34 expression. After this phase, B-cells
will lose CD10 expression whilst preserving CD19
and CD45 and gaining CD20 expression.13 The com-
bination of CD10 and CD20 with CD19 (pan-B-cell
marker) is recommended for analysing normal B-cell
differentiation to identify sequential maturation stages
(Pre-Pre B, Pre-B, immature and mature B-cells).13,14
Similarly, several studies have shown that BM-
MSC can also interact with leukaemic stem cells
(LSC) and exert an inhibitory effect on K562 cell line
proliferation through Wnt-inhibitor Dickkopf-1
(DKK-1) or by inhibiting cell cycle progression.15,16
Additionally, BM-MSC can inhibit the proliferation
of leukaemic cells from patients having chronic mye-
loid leukaemia (CML).17 However, it also has been
established that BM-MSC could have leukaemogenic
activity since BM-MSC do not inhibit Jurkat T-cell
proliferation,18 but are known to have an anti-apopto-
tic effect on acute promyelocytic leukaemia cells19 and
to promote leukaemic cell survival.20 Furthermore,
BM-MSC have been shown to play a protective role
regarding leukaemic cells isolated from acute myeloid
leukaemia (AML) and CML from apoptosis induced
by FI700 (FLT3 inhibitor)21 and imatinib,22 respec-
tively. Also, BM-MSC induce resistance to apoptosis
in acute lymphoid leukaemia (ALL) cells exposed to
asparagine depletion.23 Nevertheless, opposite effects
have been observed in non-haematological
tumours.24,25 Bergfeld and De Clerck have debated
whether mesenchymal cells are cancer cell friends or
foes, since their activity depends on their origin
(BM, adipose tissue, cord blood), differentiation state
(STRO-1+CD56+TNAP/dim21or total stromal
cells) and the type of leukaemia (acute or chronic).24
ALL is currently the most frequent malignancy
occurring in children worldwide, constituting 44%
of children’s cancers from which 80% have a B-cell
precursor immunophenotype.26,27 The World Health
Organization (WHO) recommends that leukaemic
lymphoblasts must express TdT, HLA-DR, CD19,
CD79a and CD10 in B-ALL diagnosis by ﬂow
cytometry, with variable CD20 and CD22 expres-
sion.28 Several studies have dealt with the effect ofHematoBM-MSC on B-ALL cell viability3,29 and drug
resistance;23,30 however, their role in B-ALL immuno-
phenotype regulation has only been established in
BLIN-2 cell lines, unfortunately without complete
characterisation of stromal cells.31,32
The present study has evaluated the effect of
BM-MSC on cell viability, proliferation and the
immunophenotype of primary leukaemic cells isolated
from B-ALL patients compared to cells isolated from
patients not suffering from haematological neoplasia.
This could be useful since most studies have been
performed with in vitro established cell lines and
may not reﬂect the real situation in vivo.MATERIALS AND METHODS
Isolation and characterisation of BM-MSC
BM aspirates were obtained from the iliac crest of vol-
unteer donors after signing the informed consent
form given by the ethical committee of Hospital Uni-
versitario San Ignacio. BM-MSC were isolated and
cultured as previously published6,33 and they were
used in passages 3–5 for co-culture assays. BM-
MSC phenotype assessed by ﬂow cytometry with fol-
lowing monoclonal antibodies (MAbs): FITC mouse
anti-human CD73 (clone AD2, BD Pharmingen),
PE mouse anti-human CD105 (clone SN6, Invitro-
gen), PerCP mouse anti-human CD45 (clone 2D1,
BD Biosciences) and APC mouse anti-human
CD34 (clone 581, BD Pharmingen). Data was ac-
quired in a FACS Calibur cytometer (BD Biosciences,
San Jose, CA, USA). For data analysis PAINT-
A-GATE software (BDB) was used. BM-MSC
functional assay were performed according to
previous reports6 with StemPro Osteogenesis,
Adipogenesis and Chondrogenesis Differentiation
Kits (Invitrogen).
Immunophenotype evaluation of controls and
patients with B-LLA
Patients with B-ALL (n = 6) were initially diagnosed
at the Hospital Universitario San Ignacio’s Flow
Cytometry Service in Bogotá (Colombia, South
America). B-ALL diagnosis was established according
to the WHO criteria.28,34 The B-ALL immunophe-
notype in all cases was CD19+, CD34+, TdT+
CD10+ with CD20 asynchronous expression in four
of the six samples. Percentage of inﬁltrated leukaemic
blasts was elevated with an average of 84.6% (interval:
73.2–92.1%). The mean percentage of normal BM
cells in all samples was 15%.
After morphological and immunophenotypic diag-
nosis, BM samples were sent to our laboratory, wherel Oncol Stem Cell Ther 6(3–4) Fourth Quarter 2013 hemoncstem.edmgr.com
Figure 1. Morphology of BM-MSC. BM-MSC displayed a fibroblast-like morphology after 8 (A) and 15 (B) days in culture (Olympus CK2, magnification 10·. Scale bar:
100 lm). Photographs were taken with a Sony Cybershot DSC-W7 digital camera, and colours were corrected with Adobe Photoshop.
BM MSC IN LEUKAEMIC CONTROL original research reportmononuclear cells (MNC) were isolated by Ficoll
density gradient centrifugation (Histopaque
d = 1.077 g/cm3, Sigma–Aldrich, USA) and frozen
at 70 C (Ct and B-ALL samples were frozen for
a maximum period of 30 days). After cell thawing,
immunophenotype was repeated (here on, basal
immunophenotype) with the following MAbs panel:
FITC mouse anti-human CD19 (clone HIB19, BD
Pharmingen), PE mouse anti-human CD10 (clone
HI10a, BD Biosciences), PerCP mouse anti-humanFigure 2. BM-MSC immunophenotype. Histograms showing antigen expres
CD34 (hematopoietic antigens); BM Sample 01 (A–D) and 02 (E–H). Dashe
Hematol Oncol Stem Cell Ther 6(3–4) Fourth Quarter 2013 hemoncstem.edmgr.CD45 (clone 2D1, BD Biosciences) and APC mouse
anti-human CD20 (cloneL27, BD Biosciences).
Control patients (Ct) (n = 6) BM samples were
obtained from volunteer donors with conﬁrmed
non-malignant blood disorders and evaluated in the
same way. For ﬂow cytometry analysis, BM-MNC
from Ct and B-ALL patients were selected using the
CD19/side scatter (SSC) dot-plot and CD10/side
scatter (SSC) dot-plot, respectively. Data was
acquired in a FACS Aria-II ﬂow cytometersion in freshly BM-MSC: From left to right CD105, CD73 (mesenchymal antigens) and CD45 and
d line: antigen expression; solid line: auto-fluorescence control.
com 91
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(BD Biosciences, San Jose, CA, USA) and analysed in
multiparameter PAINT-A-GATE software (BD
Bioscience).
Cell morphology evaluation and culture conditions
Fresh BM-MNC samples from Ct and B-ALL were
cytospun and stained with Wright’s dye. Photographs
were taken with a Sony Cybershot DSC-W7digital
camera and the colours corrected with Adobe Photo-
shop software.
After cell thawing, BM-MNC (Ct or B-ALL) were
cultured in two experimental conditions: (i) 2 · 104
cells were plated in direct contact with conﬂuent
BM-MSC feeder cells in RPMI medium; and (ii)ipotency assay. Cultured BM-MSC were induced to differentiate into adip
eeks. Differentiation was evidenced by lipid vacuole detection by Sudan
·) (C and D) and calcium deposits were detected by Von Kossa staining (
Hemato2 · 104 cells were plated without BM-MSC. Cultures
were maintained in a humidiﬁed atmosphere at 37 C
for 7 days.
Viability and absolute count of Ct and B-ALL cells
Ct and B-ALL BM-MNC viability were evaluated be-
fore and after culture using LIVE/DEAD Fixable
Aqua Dead Cell Stain Kit (405 nm excitation –
Molecular Probes). Cells were counted by ﬂow cytom-
etry using CountBright Absolute Counting Beads
(Molecular Probes). Absolute cell numbers per sam-
ple volume were calculated using the following for-
mula: (number of cell events)/(number of beads
events) · (beads/50 ll)/(volume of sample).ocytes (A and B), chondrocytes (C and D) and osteoblasts (E and F) in
black staining (10·) (A and B); positivity for glycosaminoglycans with
5·) (E and F) (Olympus CK2, Scale bar: 100 lm).
l Oncol Stem Cell Ther 6(3–4) Fourth Quarter 2013 hemoncstem.edmgr.com
Figure 4. Cell morphology from one Ct and two B-ALL BM samples. Microscopic evaluation of three BM samples, as examples: (A) Ct, (B) B-ALL (Pre-pre B), (C) B-ALL (Pre-B)
(scale bar: 30 lm) (Olympus CK2, magnification 100·).
Figure 5. Cell viability from Ct and B-ALL patient samples. Percentage of viable cells assessed by flow cytometry in (A) Ct and (B) B-ALL patients in basal conditions (before
culture) compared to cells cultured for 7 days in the absence () or presence (+) of BM-MSC.
BM MSC IN LEUKAEMIC CONTROL original research reportCell division estimated by carboxyﬂuorescein
diacetate succinimidyl ester (CFSE) labelling
Proliferation assays for CFSE stained BM-MNC
from Ct and B-ALL cells were performed as previ-
ously described.6 A fraction of BM-MNC was serum
deprived for 48 h to establish the highest CFSE mean
ﬂuorescence intensity (cell with no proliferation).
Both CFSE+ cells were cultured as described above.
Decrease in mean ﬂuorescence intensity (MFI) of
CFSE was determined using the cytometer Facs-II
Aria (BD Biosciences). Data analysis was performed
with the application ‘‘proliferation analysis’’ availableHematol Oncol Stem Cell Ther 6(3–4) Fourth Quarter 2013 hemoncstem.edmgr.FlowJo 7.6.5 program (TreeStar, Inc) to calculate
the proliferation index (PI).
Evaluation of Ct and B-ALL cells
immunophenotype after co-cultivation
Evaluation of cells immunophenotype was carryout
after 7 days of culture employing the same antibodies
and software used for the basal phenotype estimation.
Reliable discrimination between BM-MSC and Ct or
B-ALL cells was possible according to (i) their differ-
ent forward-scatter (FSC) and side-scatter (SSC) sig-
nals, and (ii) cells discrimination for antigencom 93
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expressions. Mean ﬂuorescence intensity (MFI) was
analysed for each antigen after 7 days of culture.
Hierarchical clustering analysis
The hierarchical clustering analysis was carried out
with the MFI information for each marker and the ra-
tio between the MFI values for each marker in B-ALL
neoplastic cells and the MFI value for the same mar-
ker in Ct. Clustering was performed by median cen-
tring and normalisation of the ﬂuorescence ratios. A
logarithmic (base 2) transformation was applied to
the ratio values in individual data sets. The resulting
normalised log 2 ratios were used for the Cluster
and Tree View programs according to procedures
previously described.35
Statistical analysis
The distribution of the data was analysed using the
Shapiro-Wilk test. Statistical tests were used for
non-parametric data. To compare culture conditionsBM samples proliferative index. Significant differences in the PI of (A) Ct
g BM-MSC *(p < 0.05).
counts from Ct and B-ALL BM samples. Comparative analysis in absolute n
ean value is indicated by the horizontal line.
Hemato(Ct or B-ALL) the Wilcoxon signed-rank test was
used using Statistix 6.0 and GraphPad Prism 5.0
for graphics. Results were considered signiﬁcant when
p value was below 0.05.RESULTS
BM-MSC characterisation
Following International Society of Cellular Therapy
recommendations,36 BM-MSC were characterised
by morphology (Figure 1A and B) and immunophe-
notype (Figure 2). All experiments were performed
with BM-MSC isolated from two independent donors
(M01 and M02). BM-MSC were negative for CD34
and CD45 and more than 98% were positive for
CD73 and CD105 antigens (Figure 2). Differentia-
tion assays showed cells with lipid vacuoles (adipo-
genic lineage), glycosaminoglycans (chondrocytes)
and alkaline phosphatase activity (osteoblasts)
(Figure 3).and (B) B-ALL cells were observed after 7 days culture in co-culture as
umbers of (A) Ct and (B) B-ALL cells after 7 days culture without () or
l Oncol Stem Cell Ther 6(3–4) Fourth Quarter 2013 hemoncstem.edmgr.com
Figure 8. Ct and B-ALL cell basal immunophenotype. FSC and SSC bivariate dot plot beads (red dots in R1 region) and cells (R2 region) were gated from representative
samples (A and F). Antigens expression is indicated (B–E) for Ct (C42 sample) and (G–J) for B-ALL (L15 sample). Panel E shows normal B-cell lineage in Ct: (1) Pre-pre-B, (2)
Pre-B and (3) B-cells.
Hematol Oncol Stem Cell Ther 6(3–4) Fourth Quarter 2013 hemoncstem.edmgr.com 95
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Figure 9. Ct cells immunophenotype analysis. Antigen expression in basal and in the different culture conditions (7 days of culture without () and with (+) BM-MSC): (A–C)
CD19, (D–F) CD45 (G–I) CD10 and (J–L) CD20 at different stages of B-cell differentiation, Pre-pre B (upper line), Pre-B (middle line) and B-cells (bottom line).
96
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cells
Fresh BM-MNC cell samples from Ct included myel-
ocytes, promonocytes, granulocytes and erythroid pre-
cursors (Figure 4A). In contrast, BM-MNC samples
from B-ALL were highly inﬁltrated (see Materials
and methods) with blasts cells having prominent
nucleoli and basophilic-agranular cytoplasm (Fig-
ure 4B and C; two patients’ samples).
Cell viability, absolute counts and proliferation
index before and after co-cultures
Cell cultures were done with and without BM-MSC.
After 7 days of culture viability, percentage in Ct and
B-ALL cells without BM-MSC had signiﬁcantly de-
creased as compared to basal cell viability (before cul-
ture) (p < 0.05); in contrast, normal and leukaemicHematocells co-cultured with BM-MSC showed higher viabil-
ity compared to cultures without BM-MSC
(p < 0.05) (Figure 5A and B).
Ct and B-ALL cells absolute counts were esti-
mated after 7 days of culture with and without BM-
MSC. More cells were observed in Ct samples when
co-cultured (Figure 6A). Similar results were ob-
served in B-ALL cells (Figure 6B). In both Ct and
B-ALL samples, the proliferation index (PI) was high-
er when co-cultured with BM-MSC (Figure 7A and
B) (p < 0.05).
Immunophenotypic analysis of Ct and B-ALL
patient cells
Basal immunophenotype was analysed in all samples.
Identiﬁcation of B-cell precursors from Ct (Figure 8A)
was based on CD45 expression in CD19+ cellsl Oncol Stem Cell Ther 6(3–4) Fourth Quarter 2013 hemoncstem.edmgr.com
BM MSC IN LEUKAEMIC CONTROL original research report
(Figure 8B–E). B-ALL leukaemic cells show homoge-
neous FSC and low SSC signals (Figure 8F), CD19
(Figure 8G), bright CD10 (Figure 8I), asynchronous
CD20 (Figure 8J) with low CD45 expression
(Figure 8G and H), consistent with a leukaemic
immunophenotype.37
After 7 days of culture, three differentiation stages
could be distinguished in Ct B-lineage cells immuno-
phenotype: Pre-pre-B, Pre-B and B-cells13,38
(Figure 8E). Therefore, the immunophenotype analy-
sis was made over these subpopulations. In Ct cells
co-cultured with BM-MSC, CD19 and CD10 expres-
sions had increased in Pre-pre B subpopulation
(Figure 9A–G). CD45 and CD20 expression had in-
creased in Pre-B subpopulation (Figure 9E–K), while
only CD19 expression decreased in B-cells
(Figure 9C).
Concerning B-ALL cell immunophenotype
analysis, CD19 expression had increased following
BM-MSC co-culture, compared to cells without
BM-MSC (Figure 10A). CD45 expression did not
change after the co-culture (Figure 10B). The greatest
increase was in CD10 (Figure 10C) and CD20
(Figure 10D) antigens.
For a global assessment of immunophenotype
patterns between Ct and B-ALL cells a hierarchical
clustering analysis was done after culture. Figure 11
shows the clusters at different experimentalFigure 10. B-ALL cells immunophenotype analysis. Antigen expression in b
(A) CD19, (B) CD45, (C) CD10 and (D) CD20. p Values are indicated.
Hematol Oncol Stem Cell Ther 6(3–4) Fourth Quarter 2013 hemoncstem.edmgr.conditions, conﬁrming CD19, CD10 and CD20
overexpression in B-ALL cells after co-culture with
BM-MSC. Hierarchical clustering analysis revealed
an association between Pre-pre B-cells and B-ALL
in basal conditions (Figure 11A) and, after co-culture,
with BM-MSC (Figure 11C). Ct and B-ALL analysis
revealed no association between cell groups after
culturing without BM-MSC (Figure 11B).DISCUSSION
Several authors have demonstrated leukaemic cell via-
bility maintenance by BM-MSC.23,29,39 Zhang et al.
demonstrated that LSC isolated from CML patients
can produce cytokines such as G-CSF which alter
stromal cell CXCL12 secretion and HSC normal
growth but favouring leukaemic cell proliferation, this
being a bidirectional interaction between LSC and
stromal cells.40
Our results regarding BM-MSC inﬂuence of leu-
kaemic cell viability maintenance agreed with these re-
ports. Herein, we have demonstrated that BM-MSC
cells from volunteer donors promoted cell survival of
normal as well as leukaemic cells (B-ALL), even after
thawing and culturing for 7 days (Figure 5). This
showed that BM-MSC had a pro-viability effect on
this type of leukaemic cell. We also found that BM-
MSC did not inhibit Ct and B-ALL cell proliferation;asal and in the different culture conditions (7 days of culture without () and with (+) BM-MSC):
com 97
Figure 11. Hierarchical cluster analysis of markers differentially expressed in B-ALL cases compared to Ct populations. (A) Basal, (B) without BM-MSC and (C) co-culture
(dotted line indicates the association between Pre-pre B and B-ALL cells). The columns show normalised log2 ratios for MFI values calculated for each analysed marker.
Protein expression levels are represented by colour codes. Red indicates over-expression respecting the mean; and green represents under-expression compared to the mean
value. Colour intensity denotes deviation magnitude (scale extends from ratio 3.00 to +3.00 log2 units).
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(Figure 7) increased after co-cultivation. Notably,
our results with BM-MSC isolated from two different
individuals (Figure 2) were very similar (data not
shown), indicating that the source of bone marrow
cells did not affect the outcome.
Recent reports have proved that mesenchymal cells
isolated from the umbilical cord can inhibit B-lym-
phocyte differentiation.41 Our results showed that
BM-MSC did affect the immunophenotype of normal
B lineage cells (Ct), increasing CD19 and CD10
expression in Pre-pre B (Figure 9 A–G). It was strik-
ing that the CD20 antigen expression was increased
after co-culture with BM-MSC in Pre-B cells becauseHematoduring this stage these cells initiate CD20 expression,
whilst pre-pre-B cells do not normally express it dur-
ing this differentiation stage.
Tabera et al have demonstrated that BM-MSC in-
duces a decrease in CD19 antigen expression in nor-
mal lymphoid cells;11 however, herein we have shown
that it changes according to lymphoid cell differentia-
tion stage (Figure 9A–C), because CD19 expression
only decreased in B-cells (Figure 9C). It is known that
CD19 antigen is involved in B-cell lineage develop-
ment, differentiation, activation42 and survival.43 It
can thus be assumed that BM-MSC promote early
lymphoid progenitor viability (Pre-pre B) by increas-
ing CD19 expression as part of lymphopoiesisl Oncol Stem Cell Ther 6(3–4) Fourth Quarter 2013 hemoncstem.edmgr.com
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homeostasis, whilst BM-MSC has an immunomodu-
lating effect in more differentiated cells (B-cells) by
decreasing CD19 antigen expression.
The immunophenotype changes of B-ALL cells in-
duced by BM-MSC were more dramatic. After
7 days, B-ALL cells cultured with BM-MSC in-
creased CD19, CD10 and CD20 compared to base-
line and without co-culture with BM-MSC. CD10
antigen is a member of the membrane-bound zinc-
dependent endopeptidases, a protein family regulating
different cellular processes by peptide-substrate cleav-
age which can inhibit cellular differentiation.44 Also,
CD10 has been used as a cell surface marker for stem
cell population identiﬁcation in breast cancer45 and
for sphere-forming cells, suggesting that this protein
can identify stem/progenitor populations. This ﬁnd-
ing is important since BM-MSC increased CD10
expression in cell populations during early stages of
differentiation (Pre-pre-B and B-ALL cells), which
might indicate that BM-MSC has a role in regulating
more primitive hematopoietic progenitors and this, in
turn, could be involved in leukaemogenesis.
BM-MSC also increased CD20 expression in
B-ALL. This antigen is a calcium-permeable cation
channel known to accelerate the G0/G1 progression
induced by insulin-like growth factor-I (IGF-1).46
Interestingly, BM-MSC produce IGF-147 inducing
leukaemic cells to increase CD20 expression, as
observed here. Interestingly, CD20 expression in
B-ALL is asynchronous, so it would have been
expected that BM-MSC could also favour an
asynchronous phenotype.
Previous studies have shown that the bone marrow
microenvironment provides higher viability and resis-
tance to chemotherapy for leukaemic cells,48–50 there-
by increasing the likelihood of relapse in patients with
B-ALL.51 It has been observed that increased CD20
expression is associated with a shorter time to
remission and disease survival.52,53 The efﬁciency ofHematol Oncol Stem Cell Ther 6(3–4) Fourth Quarter 2013 hemoncstem.edmgr.monoclonal antibody therapy, such as rituximab
(anti-CD20), has shown that this antigen is important
in B-ALL pathophysiology. The same could be con-
sidered concerning the CD19 antigen, since the use
of blinatumomab (anti-CD19) has also led to promis-
ing results.54 Moreover, increased CD10 expression
has been considered a good prognosis factor in
children having B-ALL,44,55 although others have
considered that its prognostic value should not be
considered independently56 and that it should be
analysed within the context of the other antigens.
This study has clearly demonstrated that BM-MSC
increased CD10, CD20 and CD19 expression in
blasts isolated from patients having B-ALL. Since
blast inﬁltration was high in our patients, we believe
that haematogones and the contribution of other
primitive normal cells to the immunophenotype must
have been very low, or non-existent. It is likely that
this BM-MSC-induced antigen over-expression is a
blast protection-inducing mechanism, probably
responsible for increased relapse.CONFLICT OF INTEREST
None declared.
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